The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia.

Marta De FeliceMiriam MelisSonia AroniAnna Lisa MuntoniSilvia FanniRoberto FrauPaola DevotoMarco Pistis

Published in: CNS neuroscience & therapeutics (2018)

Our study confirms previous evidence that females are less susceptible to MIA and highlights PPARα as a potential target for treatments in schizophrenia.

Keyphrases

bipolar disorder
insulin resistance
fatty acid
birth weight
type diabetes
metabolic syndrome
skeletal muscle
weight loss
weight gain